Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Santiago De Compostela – page 34

682 clinical trials in Santiago De Compostela, Spain across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Santiago De Compostela at a glance
682
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

682 trials in Santiago De Compostela

Open in trial search

Endocrine ophthalmopathy

Not recruiting

Study of VRDN-001 compared to placebo to evaluate safety and effectiveness in adults with chronic thyroid eye disease

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Viridian Therapeutics Inc.

Cholangiocarcinoma+7

Not recruiting

Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Rheumatoid arthritis

Not recruiting

Study of SAR441566 and methotrexate in adults with moderate to severe rheumatoid arthritis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Methotrexate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Non-small cell lung cancer metastatic

Not recruiting

Study comparing valemetostat tosylate plus pembrolizumab versus pembrolizumab alone in patients with advanced non-small cell lung cancer with high PD-L1 expression

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Daiichi Sankyo Inc.

Meningococcal infection

Not recruiting

Study of rMenB+OMV NZ meningococcal group B vaccine immune response and safety in previously vaccinated healthy participants aged 10 to 20 years

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Outer Membrane Vesicles (Omv) From Neisseria Meningitidis Group B Strain Nz98/254 Measured As Amount Of Total Protein Containing The Pora P1.4 Adsorbed On Aluminium Hydroxide
  • Sponsor:GlaxoSmithKline Biologicals

Study of Monthly Atacicept Injections in Patients with IgA Nephropathy (Berger Disease)

Not recruiting
InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atacicept
  • Sponsor:Vera Therapeutics Inc.

Osteoarthritis+1

Not recruiting

Study of intra-articular liraglutide (4P004) for patients with knee synovitis and osteoarthritis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Liraglutide
  • Sponsor:4moving Biotech

Hidradenitis

Not recruiting

Study of ruxolitinib cream applied to the skin for people with hidradenitis suppurativa

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Arteriosclerosis

Not recruiting

Study of pelacarsen and inclisiran in patients with atherosclerotic cardiovascular disease who have high levels of LDL cholesterol and lipoprotein(a)

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Colitis ulcerative

Not recruiting

Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Rheumatoid arthritis

Not recruiting

Study of CIT-013 at Three Different Doses for Patients with Moderately Active Rheumatoid Arthritis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Citryll B.V.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Santiago De Compostela

What the registry says about research in the country

01 Respiratory Infections Research

Innovative studies focusing on respiratory viral infections, including trials for RSV, influenza, and COVID-19 vaccines. Research aims to enhance protection in vulnerable populations, particularly adults over 60.

  • RSV and hMPV vaccine development
  • Influenza vaccine efficacy studies
  • COVID-19 vaccine co-administration research

Multiple trials evaluating both single and combination vaccine approaches for respiratory diseases.

02 Cardiovascular Studies

Research targeting cardiovascular health and prevention, with emphasis on innovative treatments for stroke and heart failure. Studies include both therapeutic interventions and preventive measures.

  • Acute cerebral ischemic stroke treatment
  • Heart failure prevention strategies
  • Cardiovascular risk management

Focus on developing new therapeutic approaches for better patient outcomes.

03 Dermatological Research

Advanced clinical investigations in dermatological conditions, particularly focusing on moderate to severe cases of psoriasis and atopic dermatitis.

  • Plaque psoriasis treatments
  • Psoriatic arthritis therapies
  • Atopic dermatitis interventions

Trials evaluating novel therapeutic agents for chronic skin conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.